Adagene Inc. (ADAG)
NASDAQ: ADAG · Real-Time Price · USD
1.920
-0.070 (-3.52%)
Aug 1, 2025, 4:00 PM - Market closed

Company Description

Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People’s Republic of China.

Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer.

The company also develops ADG116, a fully human anti-CTLA-4 antibody generated using NEObody technology, which is in phase 1b/2 clinical trials to treat advanced/metastatic solid tumors; ADG206, which is in phase 1 clinical development to treat advanced metastatic solid tumors; ADG104, anti-PD-L1 monoclonal antibody which is in phase 2 clinical development; and ADG125, a novel anti-CSF-1R mAb which is in Phase 2 clinical development.

In addition, it is developing ADG138, a HER2xCD3 POWERbody which is in pre clinical trial to treat low expressing tumors, as well as resistant/refractory tumors; ADG152, a CD20xCD3 POWERbody which is in preclincal trial to treat off-tumor toxicities; ADG153, a masked anti-CD47 IgG1 SAFEbody, wihx is in preclinical trial for the treatment of hematologic and solid tumor; and CD28 T-cell engagers, an anti-CD28 bispecific POWERbody TCEs to treat solid tumors.

The company was incorporated in 2011 and is headquartered in Suzhou, China.

Adagene Inc.
Adagene logo
CountryChina
Founded2011
IPO DateFeb 9, 2021
IndustryBiotechnology
SectorHealthcare
Employees138
CEOPeter P. Luo

Contact Details

Address:
Building C14, 4th Floor
Suzhou, 215123
China
Phone86 512 8777 3632
Websiteadagene.com

Stock Details

Ticker SymbolADAG
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUSD
IPO Price$19.00
CIK Code0001818838
CUSIP Number005329107
ISIN NumberUS0053291078
SIC Code2834

Key Executives

NamePosition
Dr. Peter P. Luo Ph.D.Co- Founder, Chairman, Chief Executive Officer and President of Research & Development
Man Kin Tam M.B.A.Chief Financial Officer and Director
Ling ZhouExecutive Director and Head of Human Resources
Dr. Qinghai Zhao Ph.D.Chief Manufacturing Officer
Yan Li M.B.A.Senior Vice President of Bioinformatics and Information Technology
Xiaohong SheSenior Vice President and Head of Clinical Operations
Dr. Guizhong Liu Ph.D.Senior Vice President of Early Drug Discovery
Alexander GoergenVice President and Head of Business Development
Dr. Jiping Zha M.D., Ph.D.Executive Vice President of Clinical Development
Dr. Songmao Zheng Ph.D.Senior Vice President of Clinical Pharmacology and Quantitative Sciences

Latest SEC Filings

DateTypeTitle
Jul 15, 20256-KReport of foreign issuer
Jul 2, 2025SCHEDULE 13G/AFiling
Jul 1, 20256-KReport of foreign issuer
May 30, 2025EFFECTNotice of Effectiveness
May 30, 2025424B5Filing
May 23, 2025F-3/AFiling
May 22, 20256-KReport of foreign issuer
May 15, 2025SCHEDULE 13G/AFiling
May 12, 2025SCHEDULE 13G/AFiling
May 9, 2025F-3Filing